Roy D. Baynes

Companies

• Eikon Therapeutics, Inc.Chief Medical Officer Feb 4, 2026 to now¹
• Nurix (United States)Board member Mar 13, 2025 to now²
• Aardvark Therapeutics, Inc.Board member Feb 12, 2025 to now³
• NateraBoard member Aug 2, 2018 to now⁴
• Travere Therapeutics, Inc.Board member Jul 26, 2016 to now⁵
• Atara Biotherapeutics, Inc.Board member Sep 12, 2018 to Jun 27, 2022⁶

Holdings

Stock this person has reported owning, from the forms officers and directors file with the SEC. See the biggest insider stakes.

Shares held

• Natera NTRA20,158 shares⁷$8.1M at $402.54Jun 26, 2026
• TTTravere Therapeutics, Inc. TVTX41,500 shares⁸$2.1M at $50.55Jun 12, 2026
• ABAtara Biotherapeutics, Inc. ATRA43,500 shares⁹$401.9K at $9.24Jun 23, 2022

As of each latest filing. The line shows shares held over time.

Recent filings

• Jun 26, 2026Granted 75 shares of Natera⁷
• Jun 26, 2026Granted 1,571 shares of Natera⁷
• Jun 12, 2026Sold 4,500 shares at $50.00 of Travere Therapeutics, Inc.⁸
• Jun 12, 2026Exercised options 4,500 shares at $21.38 of Travere Therapeutics, Inc.⁸
• May 19, 2026Granted 4,000 shares of Travere Therapeutics, Inc.¹⁰
• May 5, 2026Sold 4,500 shares at $46.65 of Travere Therapeutics, Inc.¹¹
• May 5, 2026Exercised options 4,500 shares at $18.27 of Travere Therapeutics, Inc.¹¹
• May 1, 2026Sold 9,750 shares at $44.22 of Travere Therapeutics, Inc.¹²
• May 1, 2026Exercised options 9,750 shares at $6.82 of Travere Therapeutics, Inc.¹²
• Apr 24, 2026Granted 83 shares of Natera¹³
• Apr 14, 2026Sold 6,750 shares at $42.12 of Travere Therapeutics, Inc.¹⁴
• Apr 14, 2026Sold 26,000 shares at $41.07 of Travere Therapeutics, Inc.¹⁴
• Apr 14, 2026Exercised options 6,750 shares at $17.11 of Travere Therapeutics, Inc.¹⁴
• Apr 14, 2026Exercised options 4,500 shares at $21.38 of Travere Therapeutics, Inc.¹⁴
• Apr 14, 2026Exercised options 4,500 shares at $18.27 of Travere Therapeutics, Inc.¹⁴
• Apr 14, 2026Exercised options 9,000 shares at $15.43 of Travere Therapeutics, Inc.¹⁴
• Apr 14, 2026Exercised options 8,000 shares at $17.94 of Travere Therapeutics, Inc.¹⁴
• Apr 6, 2026Sold 10,000 shares at $33.00 of Travere Therapeutics, Inc.¹⁵
• Apr 6, 2026Exercised options 10,000 shares at $26.52 of Travere Therapeutics, Inc.¹⁵
• Jan 30, 2026Granted 70 shares of Natera¹⁶
• Nov 20, 2025Sold 1,884 shares at $224.89 of Natera¹⁷
• Nov 20, 2025Sold 1,900 shares at $223.90 of Natera¹⁷
• Nov 20, 2025Sold 1,800 shares at $222.90 of Natera¹⁷
• Nov 20, 2025Sold 900 shares at $221.81 of Natera¹⁷
• Nov 20, 2025Sold 1,184 shares at $220.14 of Natera¹⁷